Background: Failures of prophylaxis against Pneumocystis carinii pneumonia (PCP) in AIDS patients do occur, but no evidence for drug resistance has yet been presented.
Introduction
Pneumocystis carinii pneumonia (PCP) remains a major opportunistic infection in persons with AIDS and immunosuppressed persons who are not infected with HIV [1] . Widespread primary prophylaxis against P. carinii has reduced the incidence of PCP [2] [3] [4] [5] , and sulfa and sulfone drugs are key prophylactic agents [6, 7] . Sulfamethoxazole is probably the only active ingredient in trimethoprim-sulfamethoxazole (TMP-Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients SMX) , which is the most widely used and effective prophylactic agent [8] [9] [10] . Dapsone, a sulfone agent, is an important second-line prophylactic agent against P. carinii [6] .
Since sulfa resistance has developed in numerous microorganisms [11] , it seems plausible that P. carinii may also became resistant to sulfa or sulfones. Because human-derived P. carinii cannot be cultivated in artificial media, determinations of resistance based on in vitro drug susceptibility testing cannot be performed. However, molecular biological methods such as the polymerase chain reaction (PCR) can be used to detect mutations in the P. carinii sulfa and sulfone drug target enzyme dihydropteroate synthase (DHPS). In a previous study [12] , we detected sequence polymorphisms at six nucleotide positions, all of which were non-synonymous and resulted in amino-acid substitutions. This suggested that the gene has been under selective evolutionary pressure such as would occur from exposure to sulfa/sulfone drugs. The purpose of the study was to determine whether DHPS mutations were associated with failures of sulfa/sulfone-containing prophylactic agents in AIDS patients who developed PCP, which might indicate the development of drug resistance.
Materials and methods
Patient specimens from the University of Michigan Medical Center (UMMC), Indiana University Medical Center (IUMC), and Ann Arbor Veterans Administration Hospital (AAVAH) were obtained for diagnostic purposes. Sixty-five patients whose discharge-coded diagnosis included 'PCP' at UMMC or AAVAH between January 1991 and April 1997 were identified. Preserved alcohol-fixed slides, paraffinembedded cytopathology tissue or frozen samples were obtained from bronchoalveolar lavage or sputum induction specimens from 22 patients at UMMC and AAVAH and 13 patients at IUMC (obtained between 1976 and 1997). The DHPS gene was successfully PCR-amplified from the identified stored specimens in 27 patients (16 of the 22 specimens from UMMC and AAVAH; 11 of the 13 specimens from IUMC), and these patients were included in the study. The study was approved by the investigational review board at each institution; clinical data were abstracted from records, and each person's use of a sulfa/sulfone-containing chemoprophylactic agent (i.e., dapsone or TMP-SMX) prior to the onset of PCP was confirmed by review of pharmacy records. Exposure to a sulfa/sulfone-containing agent was defined as the use of dapsone or TMP-SMX for at least 1 month out of the 4 months preceding the date of diagnosis of PCP.
DNA was extracted and then amplified by PCR in a PTC-100 programmable thermal controller (MJ Research, Waterstown, Massachusetts, USA) using primers A HUM and B HUM under the conditions previously described [12] [13] [14] . Negative controls were performed using 10 µl H 2 O instead of template.
Nineteen samples were subsequently subjected to nested PCR. Ten microlitres of the first PCR product was used as a template for a second round of amplification using the same program and mixture as above but with the following two primers: A NEST , 5′-CCTGATT CTTTTTTCGATGGGGGTG-3′; B NEST , 5′-GGAAC TTTCAACTTGGCAACCAC-3′. Standard precautions were used when working with the nested product to prevent contamination. Procedures for all experiments were performed with filter pipette tips in a biosafety hood. Several aliquots were taken from negative controls in the first round and run with the second set of primers for each set of nested experiments.
Reaction products were purified on 1.2% low-melt agarose (Gibco BRL, Grand Island, New York, USA) extracted with a Gel Extraction Kit (Qiagen, Chatsworth, California, USA), and sequenced on an Applied Biosystems Model 373a automated DNA sequencer (Perkin Elmer, Foster City, California, USA) using A NEST and B NEST as sequencing primers. DNA and amino-acid sequences were aligned using MacVector version 5.0 (International Biotechnologies, Inc., New Haven, Connecticut, USA).
Statistical analysis
Statistics were performed using EpiInfo (version 6.02; Centers for Disease Control and Prevention, Atlanta, Georgia, USA). Associations between sulfa and sulfone use and DHPS polymorphisms were performed using the two-tailed Fisher's exact test. A P value <0.05 was considered significant.
Results
The clinical characteristics of the 27 patients with PCP included in this study are shown in Table 1 . Twenty samples were obtained from AIDS patients between 1985 and 1997. These patients had a mean age of 35 ± 16 years (range, 1-56 years) and a mean CD4 cell count of 42 ± 82 × 10 6 /l (range, 0-215 × 10 6 /l). Seven specimens were taken from non-HIV-infected immunocompromised patients; these slides had been prepared between 1976 and 1992 (Table 1) ; CD4 cell counts had not been obtained from these patients (mean age, 20 years; range, 3 months to 75 years). Seven patients, all of whom had AIDS, received primary prophylaxis with a sulfa agent (TMP-SMX in one patient) or a sulfone agent (dapsone in six patients) for a mean duration of 11.6 ± 9.7 months (range, 3-19 months) ( Table 2 ). Six of the seven patients taking sulfa or sulfone as prophylaxis were receiving dapsone at the time of the diagnosis of PCP; one person discontinued TMP-SMX 1 month prior to the episode of PCP because of intolerance. No patient had received or were receiving sulfadiazine as therapy for toxoplasmosis prior to the episode of PCP.
Eight samples were amplified by a single round of PCR. These yielded sequences that were 720-742 nucleotides long and were identical to previously pub-lished sequences [12] . Nineteen samples were amplified by nested PCR. For these, 300-323 nucleotide-long sequences were obtained and were also identical to previously published sequences [12] . Six samples contained either one or two non-synonymous nucleotide changes identical to those previously described [12] . One sample contained mixtures of two nucleotides at both variable positions. Thus, four sequence patterns were found for the deduced amino-acid sequences ( Table 3 ). The most common P. carinii DHPS sequence, seen in 20 patients, contained Thr at codon 55 and Pro at codon 57. In one patient, DHPS had a single Pro→Ser change at codon 57. Five additional patients contained this change as well as Ala instead of Thr at codon 55. Finally, one patient had a mixture of both amino acids at both positions. The Thr 55 /Pro 57 pattern was seen in the majority of patients as well as in all of the six samples taken from patients prior to 1995 ( Table 2 ). Both of these amino acids were present in homologous DHPS genes from both murine and rat-derived P. carinii [12] . Accordingly, this was defined as the wild-type sequence. DHPS sequences containing either one or two changes or a mixture of wild-type and altered sequences were considered to be mutants. Table 4 shows that AIDS patients who had been on TMP-SMX or dapsone prophylaxis were significantly more likely to yield mutant P. carinii DHPS sequences. Amongst AIDS patients, only two (15%) out of 13 patients who had not been receiving prophylaxis with a sulfa/sulfone-containing agent had mutant DHPS genes. In contrast, five (71%) out of seven AIDS patients who had been on sulfa/sulfone prophylaxis demonstrated mutant DHPS genes. This difference was statistically significant (P = 0.022). There were no other statistically significant differences in age or CD4 cell counts between AIDS patients with wild-type and mutant P. carinii strains ( Table 1) . When non-HIV-infected persons and AIDS patients were combined, the difference became even more significant. Mutations were present in two (10%) out of 20 persons who had not received prophylaxis and five (71%) out of seven persons who received a sulfa/sulfonecontaining agent (P = 0.0032).
A sulfa/sulfone-containing agent was administered as therapy to two of the seven AIDS patients who developed PCP while receiving either dapsone or after recently taking TMP-SMX as chemoprophylaxis; the remaining five patients received pentamidine for therapy. Therapy was successful in all seven patients, including the two patients who received a sulfa/ sulfone-containing agent as therapy; P. carinii obtained from each of these two patients contained DHPS mutations. DHPS mutations were detected in patient isolates from all three participating hospitals. All of the seven mutant isolates came from the 21 patient samples obtained in 1995-1997, suggesting that mutant strains had begun to appear more recently and in multiple institutions ( Table 2 ).
There were no differences in the clinical characteristics between the 27 patients with PCP used in this study and the 51 remaining cases whose specimens could not be located (43 patients) or whose DNA could not be extracted from retrieved slides (eight patients). Thirtyseven of the 51 patients had AIDS. The AIDS patients had the following clinical characteristics: mean age, 39 years; 81% with male sex as the risk factor; mean CD4 cell count, 51 × 10 6 /l. Sulfa/sulfone prophylaxis (mean duration, 15 months) had been taken by 13 patients. Two of these patients did not survive the episode of PCP, and neither was receiving sulfa/sulfone prophylaxis. None of the 14 non-HIV-infected persons were receiving sulfa/sulfone prophylaxis; the mean age of these patients was 31 years, and 57% were male. There were no PCP-related fatalities in the non-HIV-infected group. Only three of the 51 patients had a prior episode of PCP.
Discussion
This is the first study to suggest that mutations in the P. carinii DHPS gene, the sulfa and sulfone drug target, are associated with sulfa prophylaxis failure in AIDS patients. In a previous study, we demonstrated sequence polymorphisms in the P. carinii DHPS gene from six patient isolates [12] . In the present study, we obtained partial P. carinii DHPS genetic sequences from 27 isolates from patients with PCP (20 AIDS patients) and demonstrated a statistically significant association between the presence of point mutations and prior sulfa/sulfone prophylaxis in all persons, including those who had AIDS. Three of the polymorphisms found in this study were identical to those found in the previous report [12] . DHPS point mutations have been associated with phenotypic resistance to sulfa in numerous other pathogenic microorganisms including Neisseria meningitis [15] , Streptococcus pneumoniae [16] , and Plasmodium falciparum [17] . For these organisms, a direct causal relationship between genetic mutations and phenotypic sulfa resistance has been shown by measurements of the effects of sulfa on the in vitro growth or DHPS enzymatic activity. Unfortunately, neither of these tests can be performed on human-derived P. carinii because the organism cannot be cultivated in artificial media to permit drug susceptibility testing or isolated in large enough quantities to perform enzyme assays. In addition, the DHPS-containing protein (Fas) has only been cloned and expressed from rat-derived P. carinii [18] but not from human-derived organisms. However, extrapolation of results from the rat-derived organism and human P. carinii would have limitations in that it would be complicated by the 18% difference in the amino-acid sequences between the DHPS genes in the two organisms [12] . Thus, Fas from human-derived organisms will first need to be cloned and expressed in order to assess the contribution of the observed DHPS mutations to sulfa resistance.
There is reason to suspect that one of the mutations described, Thr→Ala at codon 55, could lead to reduced sulfa/sulfone sensitivity. This amino acid is homologous to Thr 62 in the Escherichia coli enzyme, which, based on its crystal structure [19] , forms two hydrogen bonds with the pterin substrate, one of which is lost by substitution with Ala. The adjacent amino acid in the P. carinii enzyme is Arg 56 . Its homolog in the E. coli enzyme, Arg 63 , is involved in binding both to the pterin substrate and to sulfa drugs. Thus, the substitution of Ala 55 for Thr 55 in the P. carinii enzyme is likely to affect the position of Arg 56 and its ability to bind to sulfa and sulfone drugs. Indeed, a similar mutation in the P. falciparum DHPS has been found to be associated with sulfa resistance [17] . The other mutation reported here, Pro→Ser at codon 57, also occurs adjacent to Arg 56 and might similarly affect its binding to substrate and drug. Mutations near this site are responsible for drug resistance in both S. pneumoniae [16] and P. falciparum [17] . A final reason to suspect that these mutations might be associated with drug resistance is the fact that they are non-synonymous, which is indicative of positive evolutionary pressure [12] . Amino-acid sequence variations have not been demonstrated for P. carinii genes other than DHPS, although DNA sequence variation have been demonstrated in this organism [20] .
The data from this study suggest that the mutant strains of P. carinii are more likely to be found in recent patient isolates. Drug-resistant strains of P. carinii, once present, could possibly spread to patients who are not on prophylaxis, because P. carinii infections in AIDS patients may represent new infections rather than a reactivation of latent infections [21, 22] . This may account for the presence of P. carinii DHPS gene mutations in two patients with PCP who did not receive prophylaxis with a sulfa/sulfone-containing agent, although we have no direct evidence that these patients had antecedent contact with a person with AIDS or PCP. Although it is possible that chemical treatments or exposure to air during the process of extraction of DNA from stored specimens might cause DNA strand breaks, this would result in non-amplifiable DNA rather than an amino-acid substitution.
There are several potential alternative explanations for failure of sulfa/sulfone prophylaxis in AIDS patients. Regardless of the prophylactic regimen, the incidence of prophylactic failures increases when the CD4 cell count declines below 100 × 10 6 /l [6, 23, 24] . AIDS patients whose CD4 cell counts have fallen below 50 × 10 6 /l, for example, are 2.9-fold more likely to fail prophylaxis than patients with CD4 cell counts of 100-200 × 10 6 /l [24] . Inadequate dose of an agent or poor distribution of the drug into the pulmonary alveoli are additional explanations for lack of success of prophylaxis [25, 26] . Discontinuation of the prophylactic regimen due to adverse reactions are also likely to contribute to failure [27] .
Additional studies involving larger numbers of patients are needed to appraise the influence of choice of a sulfa/sulfone prophylactic agent (i.e., TMP-SMX versus dapsone) and dose to P. carinii DHPS mutations. Moreover, the significance of these mutations to therapy with a sulfa/sulfone-containing agent needs to be established. It is possible that greater concentrations of sulfa/sulfone in pulmonary tissues achieved with therapeutic doses of dapsone or TMP-SMX may result in successful treatment of PCP despite DHPS mutations, as suggested by the two patients with DHPS mutations in this report who were successfully treated with a sulfa-containing agent. However, further information is needed to determine whether the assay used in this study will enable physicians to individualize therapy for PCP or select an agent for secondary prophylaxis after an acute episode has occurred.
In summary, the results suggest that mutations in the P. carinii sulfa and sulfone target gene are associated with failures of sulfa/sulfone-containing regimens used as prophylaxis in patients with PCP. Larger prospective studies are needed to confirm whether the DHPS mutations identified in this study correlate with failures of sulfa/sulfone-containing agents as prophylaxis. Nevertheless, the results of this study underscore the need for the development of new agents for the prophylaxis and therapy of PCP.
